Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE versus TLANDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE versus TLANDO.
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE vs TLANDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone enanthate is a prodrug of testosterone, which binds to androgen receptors, activating gene transcription that leads to development of male secondary sex characteristics and anabolic effects. Estradiol valerate is a prodrug of estradiol, which binds to estrogen receptors, promoting growth and development of female reproductive tissues and secondary sex characteristics.
TLANDO (testosterone undecanoate) is an androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle mass, bone density, and secondary sexual characteristics. Testosterone is converted to dihydrotestosterone (DHT) via 5α-reductase in target tissues, exerting both androgenic and anabolic effects.
1 to 2 mL of a combination product containing 90 mg testosterone enanthate and 4 mg estradiol valerate per mL intramuscularly every 4 weeks.
TLANDO (testosterone undecanoate) is administered orally. The recommended adult dose is 225 mg twice daily (approximately every 12 hours) with a meal containing fat. Swallow capsules whole; do not chew or crush.
None Documented
None Documented
Testosterone enanthate: 4-5 days (IM). Estradiol valerate: 2-3 days (IM). Steady-state reached in ~2-3 weeks.
The terminal elimination half-life of testosterone is 10-100 minutes; however, for TLANDO (testosterone undecanoate) after oral administration, the apparent half-life is approximately 7-10 hours due to the slow release from chylomicrons and prolonged absorption.
Testosterone enanthate and estradiol valerate are metabolized in the liver. Testosterone metabolites (e.g., androsterone, etiocholanolone) are conjugated and excreted renally (90%) and fecally (~10%). Estradiol valerate is hydrolyzed to estradiol, metabolized to estrone and estriol, conjugated, and excreted primarily renally (70-80%) with ~20% biliary/fecal.
Approximately 90% of a dose is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites; about 6% is excreted in feces via bile. Unchanged testosterone accounts for less than 1% of urinary excretion.
Category D/X
Category C
Androgen
Androgen/hormone replacement